Access the full text.
Sign up today, get DeepDyve free for 14 days.
I. Pollack, M. Randall, M. Kristofik, R. Kelly, R. Selker, F. Vertosick (1990)
Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways.Journal of neurosurgery, 73 1
Nicholas Wolff, J. Richardson, M. Egorin, R. Ilaria (2003)
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.Blood, 101 12
R. McLendon, A. Friedman, D. Bigner, Erwin Meir, D. Brat, Gena Mastrogianakis, J. Olson, T. Mikkelsen, N. Lehman, K. Aldape, W. Yung, O. Bogler, J. Weinstein, S. Vandenberg, M. Berger, M. Prados, D. Muzny, M. Morgan, S. Scherer, A. Sabo, L. Nazareth, L. Lewis, O. Hall, Yiming Zhu, Yanru Ren, Omar Alvi, Jiqiang Yao, A. Hawes, S. Jhangiani, G. Fowler, A. Lucas, C. Kovar, Andrew Cree, H. Dinh, J. Santibanez, Vandita Joshi, M. Gonzalez-Garay, Christopher Miller, A. Milosavljevic, L. Donehower, D. Wheeler, R. Gibbs, K. Cibulskis, C. Sougnez, T. Fennell, Scott Mahan, Jane Wilkinson, L. Ziaugra, R. Onofrio, Toby Bloom, R. Nicol, K. Ardlie, J. Baldwin, S. Gabriel, E. Lander, L. Ding, R. Fulton, M. McLellan, J. Wallis, D. Larson, Xiaoqi Shi, R. Abbott, L. Fulton, Ken Chen, D. Koboldt, M. Wendl, R. Meyer, Yuzhu Tang, Ling Lin, John Osborne, Brian Dunford-Shore, T. Miner, K. Delehaunty, C. Markovic, Gary Swift, W. Courtney, C. Pohl, S. Abbott, Amy Hawkins, Shin Leong, C. Haipek, Heather Schmidt, M. Wiechert, T. Vickery, S. Scott, D. Dooling, A. Chinwalla, G. Weinstock, E. Mardis, R. Wilson, G. Getz, W. Winckler, R. Verhaak, M. Lawrence, Michael O’Kelly, James Robinson, Gabriele Alexe, R. Beroukhim, S. Carter, Derek Chiang, Josh Gould, Supriya Gupta, Joshua Korn, C. Mermel, J. Mesirov, S. Monti, Huy Nguyen, Melissa Parkin, Michael Reich, Nicolas Stransky, B. Weir, L. Garraway, T. Golub, M. Meyerson, L. Chin, A. Protopopov, Jianhua Zhang, I. Perna, S. Aronson, N. Sathiamoorthy, Georgi Ren, Jun Yao, W. Wiedemeyer, Hyun Kim, Won Sek, Yonghong Xiao, I. Kohane, J. Seidman, P. Park, R. Kucherlapati, P. Laird, L. Cope, J. Herman, D. Weisenberger, F. Pan, D. Berg, L. Neste, Mingyu Joo, Kornel Schuebel, S. Baylin, D. Absher, Jun Li, Audrey Southwick, Shannon Brady, A. Aggarwal, Tisha Chung, G. Sherlock, J. Brooks, R. Myers, P. Spellman, E. Purdom, L. Jakkula, A. Lapuk, H. Marr, S. Dorton, Gi Yoon, Ju Han, A. Ray, V. Wang, S. Durinck, M. Robinson, Nicholas Wang, K. Vranizan, V. Peng, E. Name, G. Fontenay, J. Ngai, J. Conboy, B. Parvin, H. Feiler, T. Speed, J. Gray, C. Brennan, N. Socci, A. Olshen, B. Taylor, A. Lash, N. Schultz, B. Reva, Yevgeniy Antipin, Alexey Stukalov, Benjamin Gross, E. Cerami, Qingqing Wei, L. Qin, V. Seshan, Liliana Villafania, Magali Cavatore, L. Borsu, A. Viale, W. Gerald, C. Sander, M. Ladanyi, C. Perou, D. Hayes, M. Topal, K. Hoadley, Yuan Qi, S. Balu, Yan Shi, Junyuan Wu, R. Penny, M. Bittner, T. Shelton, E. Lenkiewicz, S. Morris, D. Beasley, Sheri Sanders, A. Kahn, R. Sfeir, Jessica Chen, D. Nassau, Larry Feng, E. Hickey, A. Barker, D. Gerhard, J. Vockley, C. Compton, J. Vaught, P. Fielding, M. Ferguson, C. Schaefer, Jinghui Zhang, Subha Madhavan, K. Buetow, F. Collins, P. Good, M. Guyer, B. Ozenberger, Jane Peterson, E. Thomson (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 455
A. Carpentier, M. Canney, A. Vignot, V. Reina, K. Beccaria, C. Horodyckid, C. Karachi, D. Leclercq, C. Lafon, J. Chapelon, L. Capelle, P. Cornu, M. Sanson, K. Hoang-Xuan, J. Delattre, A. Idbaih (2016)
Clinical trial of blood-brain barrier disruption by pulsed ultrasoundScience Translational Medicine, 8
S. Oertel, R. Krempien, K. Lindel, A. Zabel, S. Milker-Zabel, M. Bischof, K. Lipson, P. Peschke, J. Debus, A. Abdollahi, P. Huber (2006)
Human Glioblastoma and Carcinoma Xenograft Tumors Treated by Combined Radiation and Imatinib (Gleevec®)Strahlentherapie und Onkologie, 182
Lene Uhrbom, G. Hesselager, A. Östman, M. Nistér, B. Westermark (2000)
Dependence of autocrine growth factor stimulation in platelet‐derived growth factor‐B‐induced mouse brain tumor cellsInternational Journal of Cancer, 85
J. Russell, K. Brady, W. Burgan, M. Cerra, Kelli Oswald, K. Camphausen, P. Tofilon (2003)
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.Cancer research, 63 21
A. Guha, Kathleen Dashner, Peter Black, J. Wagner, C. Stiles (1995)
Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loopInternational Journal of Cancer, 60
M. Hermanson, K. Funa, M. Hartman, L. Claesson-Welsh, C. Heldin, B. Westermark, M. Nistér (1992)
Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.Cancer research, 52 11
R. Stupp, Warren Mason, M. Bent, M. Weller, B. Fisher, M. Taphoorn, K. Bélanger, A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, Robert Janzer, Samuel Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. Cairncross, E. Eisenhauer, R. Mirimanoff (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.The New England journal of medicine, 352 10
D. Kristt, E. Reedy, Y. Yarden (1993)
Receptor tyrosine kinase expression in astrocytic lesions: similar features in gliosis and glioma.Neurosurgery, 33 1
C. Dai, J. Celestino, Yoshifumi Okada, David Louis, Greory Fuller, E. Holland (2001)
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.Genes & development, 15 15
I. Mellinghoff, N. Schultz, P. Mischel, T. Cloughesy (2012)
Will kinase inhibitors make it as glioblastoma drugs?Current topics in microbiology and immunology, 355
M. Stanulla, K. Welte, M. Hadam, T. Pietsch (2004)
Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell linesActa Neuropathologica, 89
G. Dresemann, M. Weller, M. Rosenthal, U. Wedding, W. Wagner, E. Engel, B. Heinrich, R. Mayer‐Steinacker, A. Karup-Hansen, Ø. Fluge, A. Nowak, M. Mehdorn, E. Schleyer, D. Krex, I. Olver, J. Steinbach, C. Hosius, C. Sieder, G. Sorenson, R. Parker, Z. Nikolova (2010)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomideJournal of Neuro-Oncology, 96
I. Dunn, O. Heese, P. Black (2000)
Growth Factors in Glioma Angiogenesis: FGFs, PDGF, EGF, and TGFsJournal of Neuro-Oncology, 50
F. Vassbotn, A. Östman, N. Langeland, H. Holmsen, B. Westermark, C. Heldin, M. Nistér (1994)
Activated platelet‐derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell lineJournal of Cellular Physiology, 158
M. Sporn, G. Todaro (1980)
Autocrine secretion and malignant transformation of cells.The New England journal of medicine, 303 15
E. Raymond, A. Brandes, C. Dittrich, P. Fumoleau, B. Coudert, P. Clement, M. Frénay, R. Rampling, R. Stupp, J. Kros, M. Heinrich, T. Gorlia, D. Lacombe, M. Bent (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 28
W. Berdel, Sven Vos, Juergen Maurer, D. Oberberg, Z. Marschall, Jan Schroeder, Jian Li, Wolf-Dieter Ludwig, Ernst-Dietrich Kreuser, Eckhard Thiel, Friedhelm Herrmann (1992)
Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene.Cancer research, 52 12
D. MacDonald, T. Cascino, S. Schold, J. Cairncross, G. Cairncross (1990)
Response criteria for phase II studies of supratentorial malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 7
M. Holdhoff, K. Kreuzer, C. Appelt, R. Scholz, Il-Kang Na, B. Hildebrandt, H. Riess, A. Jordan, C. Schmidt, R. Etten, B. Dörken, P. Coutre (2005)
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.Blood cells, molecules & diseases, 34 2
T. Mainprize, N. Lipsman, Yuexi Huang, Y. Meng, A. Bethune, Sarah Ironside, C. Heyn, R. Alkins, M. Trudeau, A. Sahgal, J. Perry, K. Hynynen (2019)
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility StudyScientific Reports, 9
O. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran, R. Nishikawa, A. Carpentier, K. Hoang-Xuan, P. Kavan, D. Cernea, A. Brandes, M. Hilton, L. Abrey, T. Cloughesy (2014)
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.The New England journal of medicine, 370 8
M. Weller, M. Bent, J. Tonn, R. Stupp, M. Preusser, E. Cohen‐jonathan‐moyal, R. Henriksson, É. Rhun, C. Balañà, O. Chinot, M. Bendszus, J. Reijneveld, F. Dhermain, P. French, C. Marosi, C. Watts, Ingela Oberg, G. Pilkington, B. Baumert, M. Taphoorn, M. Hegi, M. Westphal, G. Reifenberger, R. Soffietti, W. Wick (2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.The Lancet. Oncology, 18 6
Turker Kilic, J. Alberta, Pawel Zdunek, M. Acar, P. Iannarelli, T. O'reilly, E. Buchdunger, Peter Black, C. Stiles (2000)
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.Cancer research, 60 18
C. Seidel, R. Kortmann (2017)
[Radiotherapy for glioblastoma : ASCO endorses the ASTRO guideline].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 193 6
R. Matsuda, Takashi Takahashi, S. Nakamura, Y. Sekido, Keiko Nishida, Masao Seto, Tsutomu Seito, Takahiko Sugiura, Y. Ariyoshi, Toshitada Takahashi, R. Ueda (1993)
Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues.The American journal of pathology, 142 1
(1997)
The road less travelled: c-kit and stem cell factor
P. Wen, W. Yung, K. Lamborn, P. Dahia, Yanfeng Wang, B. Peng, L. Abrey, J. Raizer, T. Cloughesy, K. Fink, M. Gilbert, Susan Chang, L. Junck, D. Schiff, F. Lieberman, H. Fine, M. Mehta, H. Robins, L. Deangelis, M. Groves, V. Puduvalli, V. Levin, C. Conrad, E. Maher, K. Aldape, M. Hayes, L. Letvak, M. Egorin, R. Capdeville, R. Kaplan, A. Murgo, C. Stiles, M. Prados (2006)
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08Clinical Cancer Research, 12
C. Straube, Greeshma Elpula, J. Gempt, J. Gerhardt, Stefanie Bette, C. Zimmer, F. Schmidt-Graf, B. Meyer, S. Combs (2017)
Re-irradiation after gross total resection of recurrent glioblastomaStrahlentherapie und Onkologie, 193
M. Gilbert, J. Dignam, T. Armstrong, J. Wefel, D. Blumenthal, M. Vogelbaum, H. Colman, A. Chakravarti, S. Pugh, M. Won, R. Jeraj, P. Brown, K. Jaeckle, D. Schiff, V. Stieber, D. Brachman, M. Werner-Wasik, I. Tremont-Lukats, E. Sulman, K. Aldape, W. Curran, M. Mehta (2014)
A randomized trial of bevacizumab for newly diagnosed glioblastoma.The New England journal of medicine, 370 8
G. Chatzikonstantinou, N. Zamboglou, E. Archavlis, I. Strouthos, Eleni Zoga, Natasha Milickovic, B. Hilaris, D. Baltas, C. Rödel, N. Tselis (2018)
CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experienceStrahlentherapie und Onkologie, 194
C Straube, G Elpula, J Gempt, J Gerhardt, S Bette, C Zimmer (2017)
Re-irradiation after gross total resection of recurrent glioblastoma : spatial pattern of recurrence and a review of the literature as a basis for target volume definition, 193
European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups
R. Stupp, M. Hegi, W. Mason, M. Bent, M. Taphoorn, R. Janzer, S. Ludwin, A. Allgeier, B. Fisher, K. Bélanger, P. Hau, A. Brandes, J. Gijtenbeek, C. Marosi, C. Vecht, K. Mokhtari, P. Wesseling, S. Villà, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. Cairncross, R. Mirimanoff (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.The Lancet. Oncology, 10 5
R. Capdeville, E. Buchdunger, J. Zimmermann, A. Matter (2002)
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 1
Shoucheng Ning, D. Laird, J. Cherrington, S. Knox (2002)
The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation, 157
Purpose:Preclinical studies indicated that imatinib may have single-agent activity in glioblastoma through inhibition of tyrosine kinase activity and also that it might enhance the efficacy of radiotherapy. We therefore sought to investigate clinical efficacy in patients with newly diagnosed and recurrent glioblastoma in combination with radiotherapy. Methods: We conducted a nonrandomized, 2-arm, open-label phase II trial including patients aged 18 years or older with an ECOG performance status of 0–2 that were either newly diagnosed (arm A) with a measurable tumor (i.e., after incomplete resection or biopsy) or that were diagnosed with progression of a glioblastoma after initial therapy (arm B). Patients in arm A received 600 mg/day imatinib in combination with hypofractionated radiotherapy (2.5 Gy per fraction, 22 fractions). Patients in arm B received 600 mg/day imatinib alone or in combination with re-irradiation at various doses. In case tumor progression occurred, CCNU was added (2 cycles, 100 mg/m<sup>2</sup>) to imatinib. The primary end point was progression-free survival (PFS). The secondary end point was safety, defined as per Common Terminology Criteria for Adverse Events (version 2.0). Overall survival (OS) was analyzed as an exploratory end point. Results: Fifty-one patients were enrolled, of which 19 were included in arm A and 32 in arm B. The median follow-up was 4 (0.5–30) months in arm A and 6.5 (0.3–51.5) months in arm B. The median PFS was 2.8 months (95% CI 0–8.7) in arm A and 2.1 months (95% CI 0–11.8) in arm B. The median OS was 5.0 (0.8–30) months (95% CI 0–24.1) in arm A and 6.5 (0.3–51.5) months (95% CI 0–32.5) in arm B. The major grade 3 events were seizure (present in 17 patients), pneumonia (11 patients), and vigilance decrease (7 patients). Conclusions: Imatinib showed no measurable activity in patients with newly diagnosed or recurrent glioblastoma.
Oncology – Karger
Published: Jan 1, 2020
Keywords: Glioblastoma; Glioma; Imatinib; Gleevec
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.